Evaluation of mRNA expression of estrogen receptor β and its isoforms in human normal and neoplastic endometrium
✍ Scribed by Maciej Skrzypczak; Ivan Bieche; Sylwia Szymczak; Sengul Tozlu; Sebastian Lewandowski; Igor Girault; Katarzyna Radwanska; Cezary Szczylik; Jerzy A. Jakowicki; Rosette Lidereau; Leszek Kaczmarek
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- French
- Weight
- 102 KB
- Volume
- 110
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Endometrial cancer is well known to be estrogen‐dependent. Two estrogen receptor types, ERα and ERβ, are major mediators of a diversity of biologic functions of estrogen and play an important role in estrogen‐dependent tissues and cancers. Cloning of ERβ was followed by the discovery of a variety of its isoforms. Using real‐time RT‐PCR, the relative expression levels of ERβ1, ERβ2 (ERβcx), ERβ3, ERβ4 and ERβ5 were studied. We observed coexpression of ERβ isoforms in the endometrium and upregulation of the ERβ5 transcript in malignant endometrium. We also observed downregulation of ERβ2Δ5 transcript in neoplastic endometrium, using a semiquantitative method. Our results suggest that analyzing the changes in ERβ and its isoforms may be important in the diagnosis, prognosis and treatment of endometrial cancer. © 2004 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
We have carried out a quantitative analysis of ER-alpha and ER-beta mRNA expression in normal (n = 11) and breast cancer (n = 112) tissues using a real-time (Taq-Man) PCR assay. Expression of ER-beta mRNA variants has also been studied by triple-primer PCR assay. ER-alpha mRNA levels in normal breas
## Abstract The human ABL2 (or ARG) gene codes for a nonreceptor tyrosine kinase is involved in translocation with the ETV6 gene in human leukemia and has an altered expression in several human carcinomas. Two isoforms of Arg with different N‐termini (1A and 1B) have been described. The C‐terminal
## Abstract The actions of 17β‐estradiol (E2) and selective estrogen receptor modulators (SERMs) have been extensively investigated regarding their ability to act through estrogen receptor‐α (ERα) to perturb estrogen receptor positive (ER+) breast cancer (BC) growth. However, many BCs also express